<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>GBIHealth | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-10T11:26:33+08:00</updated>
  <subtitle>GBI专注于中国市场，为药企、器械企业和其他服务提供商建立多元的市场情报解决方案组合。GBI的高附加值行业信息、新闻和数据服务能力帮助个人和组织做出以数据为驱动的决策，更高效地沟通。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>进博会&lt;交易&gt;集锦 | “未来工厂”+基层医疗服务强化+技术升级</title>
    <updated>2020-11-09T22:00:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/rHPhiqclf8mkpPgMe0Kejg</id>
    <link href="https://mp.weixin.qq.com/s/rHPhiqclf8mkpPgMe0Kejg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞和BioNTech宣布新冠疫苗90％有效；Assembly药物II期临床失利；卫材进入甲状腺癌市场；阿斯利康携手瑞士欧姆制药</title>
    <updated>2020-11-09T22:00:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/VadpxLPyCKKVNIUuw4QFWw</id>
    <link href="https://mp.weixin.qq.com/s/VadpxLPyCKKVNIUuw4QFWw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>DEVINT | 携手创新 下沉回报 合作共赢！</title>
    <updated>2020-11-09T22:00:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/3dAF6LQY04THvmvR6u0JSQ</id>
    <link href="https://mp.weixin.qq.com/s/3dAF6LQY04THvmvR6u0JSQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>遭FDA独立专家会全面否决药物仍有机会获FDA批准；数字药品APP获批上市将影响诊疗路径；阿斯利康与博鳌乐城达成多项合作</title>
    <updated>2020-11-08T19:30:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/V3G4VRSkrsz6Cdcf3l9_4Q</id>
    <link href="https://mp.weixin.qq.com/s/V3G4VRSkrsz6Cdcf3l9_4Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>精鼎医药：真实世界研究创新与挑战并存</title>
    <updated>2020-11-08T19:30:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/EZniBUIi0m-Ony_FDX37FA</id>
    <link href="https://mp.weixin.qq.com/s/EZniBUIi0m-Ony_FDX37FA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>汇聚津门，三十位行业大咖论道细胞产业发展新趋势</title>
    <updated>2020-11-08T19:30:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/Ogix83SzGQ8gJ2D-x20SRA</id>
    <link href="https://mp.weixin.qq.com/s/Ogix83SzGQ8gJ2D-x20SRA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>进博会创新集 | 强生：多领域多维度超强跨界；辉瑞：聚力合作，深耕基层；诺华中国：探索数字赋能</title>
    <updated>2020-11-08T14:39:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/8za7EAX73ECGz9iKhhF1_w</id>
    <link href="https://mp.weixin.qq.com/s/8za7EAX73ECGz9iKhhF1_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>礼来中国携手长江药学发展基金会、上海鹰曈启动银屑病人工智能模拟与管理项目  ——首创“AI+银屑病管理”新模式</title>
    <updated>2020-11-08T14:39:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/1ePMdA6aP2uHd60v562Efw</id>
    <link href="https://mp.weixin.qq.com/s/1ePMdA6aP2uHd60v562Efw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>互联网+医保支付落地，强力BUFF加成“第四终端”</title>
    <updated>2020-11-05T21:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/KQkl3r3-vHoApCshHRaVIg</id>
    <link href="https://mp.weixin.qq.com/s/KQkl3r3-vHoApCshHRaVIg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>DEVINT | 降价93%！冠脉支架国采熔断保护价；腾讯进军医疗器械；河北省医保局：鼓励高值医用耗材改革</title>
    <updated>2020-11-05T21:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/rQYeIw8SEM5X81iR0MjiOw</id>
    <link href="https://mp.weixin.qq.com/s/rQYeIw8SEM5X81iR0MjiOw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>积极信号引股价大涨46%；三星生物加速进入中国市场；安斯泰来、天士力在华获批新进展</title>
    <updated>2020-11-05T21:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/40oizk-VEeJ8pbacUvFPBg</id>
    <link href="https://mp.weixin.qq.com/s/40oizk-VEeJ8pbacUvFPBg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康在华新布局亮相进博会  区域总部助推中国经济破浪前行</title>
    <updated>2020-11-05T21:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/mQHuWCM-rJr5xKMR0LEJFg</id>
    <link href="https://mp.weixin.qq.com/s/mQHuWCM-rJr5xKMR0LEJFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>财报解析 | 拜耳2020Q3财报：全球收入下降5.1%，中国表现亮眼</title>
    <updated>2020-11-04T19:41:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/CLKbmYOnfkbM4SlUZ4O1vg</id>
    <link href="https://mp.weixin.qq.com/s/CLKbmYOnfkbM4SlUZ4O1vg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>联拓生物III期试验在中国获批；百济抗癌新药上市申请获CDE受理；特异性TYK2抑制剂3期临床试验显示积极疗效</title>
    <updated>2020-11-04T19:41:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/sanfNKxj89x4odMYeilweQ</id>
    <link href="https://mp.weixin.qq.com/s/sanfNKxj89x4odMYeilweQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>会议精选 | 第十届给药系统与制剂研发亚洲峰会</title>
    <updated>2020-11-04T19:41:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/JmGYALY2EU4DYj562uhYow</id>
    <link href="https://mp.weixin.qq.com/s/JmGYALY2EU4DYj562uhYow" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>明儿进博会见！最后一波剧透：阿斯利康、辉瑞、赛诺菲、罗氏</title>
    <updated>2020-11-03T19:30:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/MavMH3dRi7pyeM8PqldDlw</id>
    <link href="https://mp.weixin.qq.com/s/MavMH3dRi7pyeM8PqldDlw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>财报解析 | 复星医药2020年Q3财报：收入221亿，利润增长20%</title>
    <updated>2020-11-03T19:30:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/_wK3L-ul195t38DQIKkcHg</id>
    <link href="https://mp.weixin.qq.com/s/_wK3L-ul195t38DQIKkcHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恩格列净：在华递交申请，化合物专利遇危机；罗氏药物纳入拟优先审评程序；药明巨诺昨日正式在港交所上市；一心堂澄清不实报道</title>
    <updated>2020-11-03T19:30:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/pNnn5dHuP7tnuzpW_wr8eA</id>
    <link href="https://mp.weixin.qq.com/s/pNnn5dHuP7tnuzpW_wr8eA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>财报解析 | 诺和诺德2020Q3财报，中国市场增长12%</title>
    <updated>2020-11-02T18:51:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/e7T2ERYg_Ne0T8972x37kQ</id>
    <link href="https://mp.weixin.qq.com/s/e7T2ERYg_Ne0T8972x37kQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>财报解析 | 安斯泰来2020Q3财报：全球下降5.4%，中国则增长0.5％</title>
    <updated>2020-11-02T18:51:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/rlsp8mI3tj0YNlVdgtvqcQ</id>
    <link href="https://mp.weixin.qq.com/s/rlsp8mI3tj0YNlVdgtvqcQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>